The First 90 Days That Define Success
In clinical development, the first 90 days with your Contract Research Organization (CRO) define whether a program will gain early momentum or stall before the first patient is enrolled. This initial phase is not simply onboarding — it is where alignment, trust, and shared accountability take shape. The foundations built during this period determine how effectively both sides can navigate complexity, manage risk, and deliver results under pressure. At Ergomed, we see these early days as an activation sprint — a concentrated period where strategic intent meets operational execution.
The difference between a transactional vendor relationship and a true strategic partnership becomes evident immediately. When a sponsor treats its CRO as a partner — one that shares responsibility, communicates openly, and works toward a single purpose — the benefits are measurable. The goal in those early weeks is simple but critical: accelerate the path to patient enrollment while safeguarding quality, compliance, and scientific integrity. As our teams often say, “The primary objective is strategically aligning to accelerate that critical path—to get sites activated and patients enrolled.”
Momentum, in this context, does not happen by chance. It is engineered through disciplined preparation and precise coordination. Every successful collaboration begins with a clear roadmap that anticipates potential delays before they appear. Sponsors and CROs must define governance structures, communication protocols, and escalation pathways early on. Master documents — from the final protocol to the budget and the Master Service Agreement — should progress in parallel rather than sequentially. By eliminating dependencies and overlap, teams gain weeks that are often lost in conventional startup timelines.
The kickoff meeting, too often treated as a formality, should instead be viewed as a strategic inflection point. Pre-alignment discussions ensure every stakeholder understands not just deliverables, but the rationale behind them. Transparency during this stage sets the tone for collaboration and accountability. As one of our project leads notes, “The most important ingredient of a successful relationship is transparency.” When every function — clinical operations, regulatory, data management, and medical oversight — operates with shared visibility, the project transforms from a list of tasks into a coordinated mission.
At Ergomed, we build startup processes that run in parallel rather than sequence. While feasibility assessments are underway, site engagement and system setup move forward simultaneously. Site selection relies not only on analytics but also on understanding site capabilities, local regulatory nuances, and institutional review board (IRB) structures. As we often remind our teams, “It’s not just about analytics. Site engagement and capability assessment remain at the heart of smart feasibility.” This approach minimizes bottlenecks and maintains pace without compromising quality.
Flexibility is another defining quality of an effective sponsor–CRO partnership. Change is inevitable — protocols evolve, regulatory expectations shift, vendors delay deliverables. What separates resilient teams from reactive ones is readiness. Structured change management, clear communication lines, and an agreed escalation process ensure that even when studies pivot, the overall strategy remains intact. Adaptability, grounded in preparation, preserves both speed and control.
Risk management, too, begins with transparency. Sponsors must ensure agreements and core documents are complete, while CROs proactively surface risks and mitigation plans. Collaboration on this level turns escalation into problem-solving, not blame. The ability to anticipate rather than react to risk is what ultimately protects timelines.
Acceleration, in the Ergomed philosophy, is not about cutting corners — it is about leveraging experience. Years of operational intelligence, refined systems, and specialized teams enable faster execution and sharper decision-making. By anticipating bottlenecks, setting realistic expectations, and communicating relentlessly, sponsors and CROs can compress the critical path from contract signature to first patient in, without sacrificing quality or compliance.
Because in the end, the first 90 days define everything that follows. When both sides invest in planning, clarity, and disciplined execution, they set the rhythm for the entire study. The advice we give our partners is simple but earned: plan relentlessly, communicate openly, and act decisively.